Market Research

Chronic Kidney Disease (CKD) Drugs Market (Drug Class: ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis-stimulating Agents, Diuretics, and Others) - Global Industry Analysis, Size, Share, Growth, Tr

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 143 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827851
Best Price Guarantee
Price from $5,795
Length 143 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827851

Chronic Kidney Disease (CKD) Drugs Market (Drug Class: ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis-stimulating Agents, Diuretics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Chronic Kidney Disease (CKD) Drugs Market – Scope of Report

TMR’s report on the global chronic kidney disease (CKD) drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global chronic kidney disease (CKD) drugs market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic kidney disease (CKD) drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the chronic kidney disease (CKD) drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global chronic kidney disease (CKD) drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global chronic kidney disease (CKD) drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global chronic kidney disease (CKD) drugs market.

The report delves into the competitive landscape of the global chronic kidney disease (CKD) drugs market. Key players operating in the global chronic kidney disease (CKD) drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global chronic kidney disease (CKD) drugs market profiled in this report.

Key Questions Answered in Global chronic kidney disease (CKD) drugs Market Report
  • What is the sales/revenue generated by chronic kidney disease (CKD) drugs across all regions during the forecast period?
  • What are the opportunities in the global chronic kidney disease (CKD) drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Chronic Kidney Disease (CKD) Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global chronic kidney disease (CKD) drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global chronic kidney disease (CKD) drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global chronic kidney disease (CKD) drugs market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease (CKD) Drugs Market
4. Market Overview
  4.1. Introduction
  4.1.1. Product Definition
  4.1.2. Industry Evolution/Developments
  4.2. Overview
  4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
  4.4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product/Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Drug Class
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Drug Class, 2020-2034
  6.3.1. ACE Inhibitors
  6.3.2. Angiotensin-II Receptor Blockers
  6.3.3. Calcium Channel Blockers
  6.3.4. Beta Blockers
  6.3.5. Erythropoiesis-stimulating Agents (ESAs)
  6.3.6. Diuretics
  6.3.7. Others
  6.4. Market Attractiveness Analysis, by Drug Class
7. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by End-user
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by End-user, 2020-2034
  7.3.1. Hospitals
  7.3.2. Specialty Clinics
  7.4. Market Attractiveness Analysis, by End-user
8. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Region
  8.1. Key Findings
  8.2. Market Value Forecast, by Region, 2020-2034
  8.2.1. North America
  8.2.2. Europe
  8.2.3. Asia Pacific
  8.2.4. Latin America
  8.2.5. Middle East & Africa
  8.3. Market Attractiveness Analysis, by Region
9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
  9.1. Introduction
  9.2. Key Findings
  9.3. Market Value Forecast, by Drug Class, 2020-2034
  9.3.1. ACE Inhibitors
  9.3.2. Angiotensin-II Receptor Blockers
  9.3.3. Calcium Channel Blockers
  9.3.4. Beta Blockers
  9.3.5. Erythropoiesis-stimulating Agents (ESAs)
  9.3.6. Diuretics
  9.3.7. Others
  9.4. Market Value Forecast, by End-user, 2020-2034
  9.4.1. Hospitals
  9.4.2. Specialty Clinics
  9.5. Market Value Forecast, by Country, 2020-2034
  9.5.1. U.S.
  9.5.2. Canada
  9.6. Market Attractiveness Analysis
  9.6.1. By Drug Class
  9.6.2. By End-user
  9.6.3. By Country
10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
  10.1. Introduction
  10.2. Key Findings
  10.3. Market Value Forecast, by Drug Class, 2020-2034
  10.3.1. ACE Inhibitors
  10.3.2. Angiotensin-II Receptor Blockers
  10.3.3. Calcium Channel Blockers
  10.3.4. Beta Blockers
  10.3.5. Erythropoiesis-stimulating Agents (ESAs)
  10.3.6. Diuretics
  10.3.7. Others
  10.4. Market Value Forecast, by End-user, 2020-2034
  10.4.1. Hospitals
  10.4.2. Specialty Clinics
  10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  10.5.1. Germany
  10.5.2. U.K.
  10.5.3. France
  10.5.4. Italy
  10.5.5. Spain
  10.5.6. Rest of Europe
  10.6. Market Attractiveness Analysis
  10.6.1. By Drug Class
  10.6.2. By End-user
  10.6.3. By Country/Sub-region
11. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
  11.1. Introduction
  11.2. Key Findings
  11.3. Market Value Forecast, by Drug Class, 2020-2034
  11.3.1. ACE Inhibitors
  11.3.2. Angiotensin-II Receptor Blockers
  11.3.3. Calcium Channel Blockers
  11.3.4. Beta Blockers
  11.3.5. Erythropoiesis-stimulating Agents (ESAs)
  11.3.6. Diuretics
  11.3.7. Others
  11.4. Market Value Forecast, by End-user, 2020-2034
  11.4.1. Hospitals
  11.4.2. Specialty Clinics
  11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  11.5.1. China
  11.5.2. Japan
  11.5.3. India
  11.5.4. Australia & New Zealand
  11.5.5. Rest of Asia Pacific
  11.6. Market Attractiveness Analysis
  11.6.1. By Drug Class
  11.6.2. By End-user
  11.6.3. By Country/Sub-region
12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
  12.1. Introduction
  12.2. Key Findings
  12.3. Market Value Forecast, by Drug Class, 2020-2034
  12.3.1. ACE Inhibitors
  12.3.2. Angiotensin-II Receptor Blockers
  12.3.3. Calcium Channel Blockers
  12.3.4. Beta Blockers
  12.3.5. Erythropoiesis-stimulating Agents (ESAs)
  12.3.6. Diuretics
  12.3.7. Others
  12.4. Market Value Forecast, by End-user, 2020-2034
  12.4.1. Hospitals
  12.4.2. Specialty Clinics
  12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  12.5.1. Brazil
  12.5.2. Mexico
  12.5.3. Rest of Latin America
  12.6. Market Attractiveness Analysis
  12.6.1. By Drug Class
  12.6.2. By End-user
  12.6.3. By Country/Sub-region
13. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
  13.1. Introduction
  13.2. Key Findings
  13.3. Market Value Forecast, by Drug Class, 2020-2034
  13.3.1. ACE Inhibitors
  13.3.2. Angiotensin-II Receptor Blockers
  13.3.3. Calcium Channel Blockers
  13.3.4. Beta Blockers
  13.3.5. Erythropoiesis-stimulating Agents (ESAs)
  13.3.6. Diuretics
  13.3.7. Others
  13.4. Market Value Forecast, by End-user, 2020-2034
  13.4.1. Hospitals
  13.4.2. Specialty Clinics
  13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  13.5.1. GCC Countries
  13.5.2. South Africa
  13.5.3. Rest of Middle East & Africa
  13.6. Market Attractiveness Analysis
  13.6.1. By Drug Class
  13.6.2. By End-user
  13.6.3. By Country/Sub-region
14. Competition Landscape
  14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  14.2. Market Share Analysis, by Company (2023)
  14.3. Company Profiles
  14.3.1. F. Hoffmann-La Roche Ltd.
  14.3.1.1. Company Overview
  14.3.1.2. Product Portfolio
  14.3.1.3. SWOT Analysis
  14.3.1.4. Financial Overview
  14.3.1.5. Strategic Overview
  14.3.2. Pfizer, Inc.
  14.3.2.1. Company Overview
  14.3.2.2. Product Portfolio
  14.3.2.3. SWOT Analysis
  14.3.2.4. Financial Overview
  14.3.2.5. Strategic Overview
  14.3.3. Sanofi
  14.3.3.1. Company Overview
  14.3.3.2. Product Portfolio
  14.3.3.3. SWOT Analysis
  14.3.3.4. Financial Overview
  14.3.3.5. Strategic Overview
  14.3.4. GSK plc
  14.3.4.1. Company Overview
  14.3.4.2. Product Portfolio
  14.3.4.3. SWOT Analysis
  14.3.4.4. Financial Overview
  14.3.4.5. Strategic Overview
  14.3.5. Kissei Pharmaceutical Co., Ltd.
  14.3.5.1. Company Overview
  14.3.5.2. Product Portfolio
  14.3.5.3. SWOT Analysis
  14.3.5.4. Financial Overview
  14.3.5.5. Strategic Overview
  14.3.6. AbbVie Inc.
  14.3.6.1. Company Overview
  14.3.6.2. Product Portfolio
  14.3.6.3. SWOT Analysis
  14.3.6.4. Financial Overview
  14.3.6.5. Strategic Overview
  14.3.7. Akebia Therapeutics, Inc.
  14.3.7.1. Company Overview
  14.3.7.2. Product Portfolio
  14.3.7.3. SWOT Analysis
  14.3.7.4. Financial Overview
  14.3.7.5. Strategic Overview
  14.3.8. AstraZeneca
  14.3.8.1. Company Overview
  14.3.8.2. Product Portfolio
  14.3.8.3. SWOT Analysis
  14.3.8.4. Financial Overview
  14.3.8.5. Strategic Overview
  14.3.9. Amgen Inc.
  14.3.9.1. Company Overview
  14.3.9.2. Product Portfolio
  14.3.9.3. SWOT Analysis
  14.3.9.4. Financial Overview
  14.3.9.5. Strategic Overview
  14.3.10. Teva Pharmaceutical Industries Ltd.
  14.3.10.1. Company Overview
  14.3.10.2. Product Portfolio
  14.3.10.3. SWOT Analysis
  14.3.10.4. Financial Overview
  14.3.10.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings